Human pathology最新文献

筛选
英文 中文
Marginal zone lymphoma of extranodal sites: A review with an emphasis on diagnostic pitfalls and differential diagnosis with reactive conditions. 结节外边缘区淋巴瘤:以诊断陷阱和与反应性疾病的鉴别诊断为重点的综述。
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-13 DOI: 10.1016/j.humpath.2024.105683
Roman Segura-Rivera, Sergio Pina-Oviedo
{"title":"Marginal zone lymphoma of extranodal sites: A review with an emphasis on diagnostic pitfalls and differential diagnosis with reactive conditions.","authors":"Roman Segura-Rivera, Sergio Pina-Oviedo","doi":"10.1016/j.humpath.2024.105683","DOIUrl":"10.1016/j.humpath.2024.105683","url":null,"abstract":"<p><p>Marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) represents 8% of all B-cell lymphomas and it is the most common small B-cell lymphoma arising at extranodal sites. The gold-standard test to establish a diagnosis of MALT lymphoma remains histopathologic analysis with the aid of immunohistochemistry (IHC) and/or flow cytometry immunophenotypic analysis. MALT lymphoma represents a progression from a persistent chronic inflammatory process, and therefore distinguishing MALT lymphoma from chronic inflammation by histopathology may be challenging in some cases. Despite recent trends to consider IGH rearrangement/clonality as a confirmatory diagnostic test of MALT lymphoma, this method is far from ideal for this purpose since a positive or a negative result does not necessarily confirm or exclude that a process is lymphoma or reactive. This test must be correlated with the morphologic findings. Moreover, MALT lymphoma may arise in association with underlying autoimmune conditions where clonal lymphoid populations are not uncommonly detected. Therefore, we believe that an integrated approach including detailed morphologic review in combination with IHC and/or flow cytometry is best to establish a diagnosis of MALT lymphoma in most cases. We present helpful morphologic tips to avoid potential diagnostic pitfalls at some of the most common extranodal sites, including the stomach, ocular adnexa/conjunctiva, salivary gland, lung, thymus, breast, thyroid, small and large intestine and the dura. The differential diagnosis of MALT lymphoma with IgG4-related disease is also discussed.</p>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105683"},"PeriodicalIF":2.7,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perinephric myxoid pseudotumor of fat: A series of 13 cases and literature review. 肾周脂肪肌样假瘤:13 例系列病例及文献综述》(Perinephric Myxoid Pseudotumor of Fat: A Series of 13 Cases and Literature Review.
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-12 DOI: 10.1016/j.humpath.2024.105681
Qingqing Wu, Ezra Baraban, John M Gross
{"title":"Perinephric myxoid pseudotumor of fat: A series of 13 cases and literature review.","authors":"Qingqing Wu, Ezra Baraban, John M Gross","doi":"10.1016/j.humpath.2024.105681","DOIUrl":"10.1016/j.humpath.2024.105681","url":null,"abstract":"<p><p>Perinephric myxoid pseudotumor of fat (PMPF) is a recently described and rare retroperitoneal mass-forming lesion whose clinical significance chiefly involves mimicry of a variety of soft tissue tumors. For unknown reasons, it commonly occurs in male patients with underlying non-neoplastic renal diseases and/or type 2 diabetes (DMT2). A total of 55 cases have been reported in the literature. Recently, we have encountered 13 such masses with peculiar histologic features; thus, we sought to investigate our experience and review the clinicopathologic characteristics of the literature. Our series confirms that PMPF frequently occurs in adult male patients (11/13, 85%), with an average age of 66 years, and commonly co-occurs with renal disease, such as DMT2 (2/13, 15%), end-stage renal disease (ESRD) (5/13, 39%), renal cysts (4/13, 31%), concurrent or prior renal neoplasia (2/13; 15%), and myeloma/lymphoma (2/13; 15%). Histologic evaluation shows lipomatous masses commonly showing variable amounts of fat necrosis, myxoid degeneration, lymphoplasmacytic inflammation and lacking atypical hyperchromatic stromal spindle cells. Unusual histologic features include extramedullary hematopoiesis (1/13, 8%), hemosiderin deposition (4/13, 31%), and small wisps of mature smooth muscle (6/13, 46%). All cases tested were negative for MDM2 and did not show an increased ratio of IgG4<sup>+</sup>/IgG<sup>+</sup> plasma cells. Our study confirms the clinical and pathologic features of PMPF and expands its histologic spectrum, underscoring the importance of this entity as a benign pseudotumor which should be included in the differential diagnosis of other fat-containing retroperitoneal masses, particularly well-differentiated liposarcoma.</p>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105681"},"PeriodicalIF":2.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical use of circulating tumor DNA analysis in patients with lymphoma. 循环肿瘤 DNA 分析在淋巴瘤患者中的临床应用。
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-02 DOI: 10.1016/j.humpath.2024.105679
Bettina Bisig, Karine Lefort, Sylvain Carras, Laurence de Leval
{"title":"Clinical use of circulating tumor DNA analysis in patients with lymphoma.","authors":"Bettina Bisig, Karine Lefort, Sylvain Carras, Laurence de Leval","doi":"10.1016/j.humpath.2024.105679","DOIUrl":"10.1016/j.humpath.2024.105679","url":null,"abstract":"<p><p>The analysis of circulating tumor DNA (ctDNA) in liquid biopsy specimens has an established role for the detection of predictive molecular alterations and acquired resistance mutations in several tumors. The low-invasiveness of this approach allows for repeated sampling and dynamic monitoring of disease evolution. Originating from the entire body tumor bulk, plasma-derived ctDNA reflects intra- and interlesional genetic heterogeneity. In the management of lymphoma patients, ctDNA quantification at various timepoints of the patient's clinical history is emerging as a complementary tool that may improve risk stratification, assessment of treatment response and early relapse detection during follow-up, most prominently in patients with diffuse large B-cell lymphoma or classic Hodgkin lymphoma. While liquid biopsies have not yet entered standard-of-care treatment protocols in these settings, several trials have provided evidence that at least a subset of lymphoma patients may benefit from the introduction of liquid biopsies into daily clinical care. In parallel, continuous technological developments have enabled highly sensitive ctDNA assessment methods, which span from locus-specific techniques identifying single hotspot mutations, to sequencing panels and genome-wide approaches that explore broader genetic and epigenetic alterations. Here, we provide an overview of current methods and ongoing technical developments for ctDNA evaluation. We also summarize the most important data from a selection of clinical studies that have explored the clinical use of ctDNA in several lymphoma entities.</p>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105679"},"PeriodicalIF":2.7,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Classic Hodgkin lymphoma: An illustrative review of select diagnostic limitations and immunomorphological challenges. 经典霍奇金淋巴瘤:对部分诊断局限性和免疫形态学挑战的说明性回顾。
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-02 DOI: 10.1016/j.humpath.2024.105678
Siba El Hussein, Dennis P O'Malley
{"title":"Classic Hodgkin lymphoma: An illustrative review of select diagnostic limitations and immunomorphological challenges.","authors":"Siba El Hussein, Dennis P O'Malley","doi":"10.1016/j.humpath.2024.105678","DOIUrl":"10.1016/j.humpath.2024.105678","url":null,"abstract":"<p><p>The diagnosis of classic Hodgkin lymphoma (CHL) in clinical practice remains reliant on tissue morphological and immunohistochemical evaluation. In this article, we illustrate specific scenarios that we have encountered in our clinical practice pertaining to diagnostic challenges in CHL. We begin with select presentations of morphologic variants of CHL and then discuss certain immunophenotypic deviations from what is deemed \"normal patterns\" of antigen expression by HRS cells. Lastly, we discuss mimickers of HRS cells, in lymphomatous and non-lymphomatous conditions.</p>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":" ","pages":"105678"},"PeriodicalIF":2.7,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1/TSC2-Mutations: A Series of 4 cases and a review of the literature 与结节性硬化症或MTOR、TSC1/TSC2突变相关的转移性肾细胞癌伴有纤维瘤基质:4例系列病例及文献综述。
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-01 DOI: 10.1016/j.humpath.2024.105680
Sounak Gupta , Michael R. McCarthy , Melissa Y. Tjota , Tatjana Antic , John C. Cheville
{"title":"Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1/TSC2-Mutations: A Series of 4 cases and a review of the literature","authors":"Sounak Gupta ,&nbsp;Michael R. McCarthy ,&nbsp;Melissa Y. Tjota ,&nbsp;Tatjana Antic ,&nbsp;John C. Cheville","doi":"10.1016/j.humpath.2024.105680","DOIUrl":"10.1016/j.humpath.2024.105680","url":null,"abstract":"<div><div>Renal cell carcinoma with fibromyomatous stroma (RCCfms) are characterized by a constellation of morphologic findings that include elongated tubules lined by cells with clear to pale eosinophilic cytoplasm and intersecting bands of smooth muscle stroma. Consistent immunohistochemistry findings in RCCfms include diffuse positivity for carbonic anhydrase 9 and variable expression of keratin 7. Molecular profiling of such tumors show either pathogenic alterations of the <em>ELOC</em> (<em>TCEB1</em>) gene, or alterations of <em>MTOR</em>, <em>TSC1</em>, and <em>TSC2</em>. <em>MTOR</em>, <em>TSC1</em>/<em>TSC2</em>-altered RCCfms (M/TSC-RCCfms) has been reported both in the sporadic setting and in association with tuberous sclerosis complex (TSC). The importance of accurate diagnosis of M/TSC-RCCfms includes prompting germline testing in the appropriate clinical context. In addition, it can lead to patient management strategies that are focused on the preservation of renal function, as TSC patients often have multifocal and bilateral disease. As diagnostic criteria for M/TSC-RCCfms have only been recently established, additional data are needed to understand the natural history of this disease. Herein, we report 6 patients with metastatic M/TSC-RCCfms, including four patients from our institutional archives (four males, aged 36–58 years at nephrectomy), and two additional cases reported in the literature. Five patients had TSC, and the sixth had an <em>MTOR</em>-altered RCCfms. The majority of patients (5/6, 83%) presented with regional lymph node involvement and one patient developed metastases to the lung. All patients were alive at last follow up (median follow-up of 85 months). Our report is intended to raise awareness regarding rare instances of metastatic behavior for M/TSC-RCCfms.</div></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"153 ","pages":"Article 105680"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SALL4 expression is very rare in endometrial endometrioid and serous carcinoma SALL4 在子宫内膜样癌和浆液性癌中的表达非常罕见。
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-01 DOI: 10.1016/j.humpath.2024.105675
Meline Brouard, Mousa Mobarki, Michel Péoc'h, Georgia Karpathiou
{"title":"SALL4 expression is very rare in endometrial endometrioid and serous carcinoma","authors":"Meline Brouard,&nbsp;Mousa Mobarki,&nbsp;Michel Péoc'h,&nbsp;Georgia Karpathiou","doi":"10.1016/j.humpath.2024.105675","DOIUrl":"10.1016/j.humpath.2024.105675","url":null,"abstract":"","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"153 ","pages":"Article 105675"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multinucleated tumor cells and micropapillary morphology appear to be predictors of poor prognosis in renal cell carcinoma with papillary and oncocytic features 多核肿瘤细胞和微乳头状形态似乎是具有乳头状和肿瘤细胞特征的肾细胞癌预后不良的预测因素。
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-01 DOI: 10.1016/j.humpath.2024.105677
Ting Zhao, Thomas Denize, Hanzhang Wang, Adam S. Fisch, Shulin Wu, Chin-Lee Wu, Kristine M. Cornejo
{"title":"Multinucleated tumor cells and micropapillary morphology appear to be predictors of poor prognosis in renal cell carcinoma with papillary and oncocytic features","authors":"Ting Zhao,&nbsp;Thomas Denize,&nbsp;Hanzhang Wang,&nbsp;Adam S. Fisch,&nbsp;Shulin Wu,&nbsp;Chin-Lee Wu,&nbsp;Kristine M. Cornejo","doi":"10.1016/j.humpath.2024.105677","DOIUrl":"10.1016/j.humpath.2024.105677","url":null,"abstract":"<div><div>Renal cell carcinoma with papillary and oncocytic features (RCC-PO) are poorly understood, partially due to conflicting results in multiple studies. The histological features that predict behavior of RCC-PO have not been elucidated. The aim is to review clinicopathologic features and to correlate clinical outcomes of patients with RCC-PO to further expand our knowledge on these heterogeneous tumors. An archival search was done for “RCC” and “papillary,” and tumors with &gt;50% papillary and oncocytic features were included. Clinicopathologic data including tumor size, grade, stage, molecular and immunohistochemical testing when performed, and follow-up data were collected. Using multivariate analyses, correlation between histological features, tumor stage and prognosis were analyzed. Sixty-one patients with RCC-PO were identified of which 49 (80%) were male with a median age of 65 (range: 36–93) years, and a mean tumor size of 5.2 (range: 1–21.5) cm. Micropapillary features were seen in 4, bizarre nuclei (at least 3 times larger or with irregular shape) in 6, multinucleated tumor cells (MTC) in 15, single or small clusters (SSC) (made of 2–3 tumor cells) located away from areas of necrosis in 16, and striking eosinophilic cytoplasmic inclusions in 3 tumors, respectively. Thirty-six (59%) tumors were high-grade (WHO/ISUP grade 3–4), and 23 (38%) had a high stage (≥pT3 or pN1). Tumors were positive for AMACR (15/16) and CK7 (13/17), with preserved FH (7/7) staining and were all negative for CD117 (0/7), ALK, TFE3, cathepsin K, Melan A, and HMB45 (0/4, each). Three tumors underwent chromosomal microarray (CMA) plus gene fusion assay, and FISH and germline testing for <em>FLCN</em> and <em>MET</em> gene alterations by PCR were done on 1 each. Ten (16%) patients had a local recurrence (LR) or metastasis after nephrectomy; 4 died of disease (2 had tumors with micropapillary features), with a median follow-up of 7 (range: 0.01–19) years. Tumors with micropapillary features showed significantly higher RCC-PO-related mortality (50% vs. 3.5%, p &lt; 0.001). In multivariable analysis, SSC correlated with a higher stage (HR: 11.95; p = 0.005); micropapillary features (HR: 18.42; p = 0.017) and MTC (HR: 180.22; p = 0.036) with presence of metastasis/LR; and micropapillary features with a higher RCC-PO-related mortality (HR: 60.35; p = 0.036). RCC-PO are cytogenetically heterogeneous with overlapping features of various renal neoplasms. Micropapillary features and MTC appear to be independent predictors of poor outcomes in these tumors.</div></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"153 ","pages":"Article 105677"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinically aggressive follicular cell-derived thyroid carcinoma: A comprehensive series with histomolecular characterization and discovery of novel gene fusions 临床侵袭性滤泡细胞源性甲状腺癌:组织分子特征和新型基因融合的综合系列研究
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-01 DOI: 10.1016/j.humpath.2024.105674
Ziyad Alsugair , Francoise Descotes , Jonathan Lopez , Hélène Lasolle , Françoise Borson Chazot , Jean-Christophe Lifante , Myriam Decaussin-Petrucci
{"title":"Clinically aggressive follicular cell-derived thyroid carcinoma: A comprehensive series with histomolecular characterization and discovery of novel gene fusions","authors":"Ziyad Alsugair ,&nbsp;Francoise Descotes ,&nbsp;Jonathan Lopez ,&nbsp;Hélène Lasolle ,&nbsp;Françoise Borson Chazot ,&nbsp;Jean-Christophe Lifante ,&nbsp;Myriam Decaussin-Petrucci","doi":"10.1016/j.humpath.2024.105674","DOIUrl":"10.1016/j.humpath.2024.105674","url":null,"abstract":"<div><div>Thyroid cancer rates are increasing, mostly with a good prognosis and less than 2 % of cases are more aggressive. Recent efforts focus on understanding molecular events predicting tumor aggressiveness and treatment targets in advanced thyroid cancer. This study concerned 57 patients with aggressive metastatic, and/or radioiodine-refractory thyroid carcinomas, excluding anaplastic cases. Molecular profiling, including next-generation sequencing and RNA sequencing, was conducted to dissect the complex molecular landscape of these aggressive tumors. Histopathological analysis indicated that papillary carcinomas and high-grade thyroid carcinomas were predominant. The molecular analysis revealed a spectrum of mutations, with prevalent occurrences of BRAF V600E, TERT promoter, and RAS mutations. RNA sequencing identified ten gene fusions, such as <em>NTRK</em> and <em>RET</em> fusions. Three novel fusions were discovered: <em>UGGT1::TERT</em>, <em>BTBD9::TERT</em>, and <em>TG::IGF1R</em>, potentially driving aggressive behavior. <em>UGGT1::TERT</em> was linked to radioiodine-refractory tall cell PTC, <em>BTBD9::TERT</em> to high-grade follicular PTC, and <em>TG::IGF1R</em> to oncocytic carcinoma. These findings underscore the importance of <em>TERT</em> alterations in aggressive phenotypes and offer insights into molecular mechanisms guiding targeted therapies. Further research is necessary to confirm their significance as diagnostic and prognostic markers in thyroid cancer.</div></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"153 ","pages":"Article 105674"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Information for Authors 作者须知
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-01 DOI: 10.1016/S0046-8177(24)00197-7
{"title":"Information for Authors","authors":"","doi":"10.1016/S0046-8177(24)00197-7","DOIUrl":"10.1016/S0046-8177(24)00197-7","url":null,"abstract":"","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"153 ","pages":"Article 105688"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding the spectrum of fusion partners for cystic TFE3-rearranged renal cell carcinomas: A report of a MAPK1IP1L::TFE3-rearranged renal cell carcinoma 扩大囊性 TFE3 重组肾细胞癌融合伙伴的范围:一例MAPK1IP1L::TFE3重组肾细胞癌的报告。
IF 2.7 2区 医学
Human pathology Pub Date : 2024-11-01 DOI: 10.1016/j.humpath.2024.105654
Burak Tekin, Ruqin Chen, Rumeal D. Whaley, Jordan P. Reynolds, Hussam Al-Kateb, John C. Cheville, Sounak Gupta
{"title":"Expanding the spectrum of fusion partners for cystic TFE3-rearranged renal cell carcinomas: A report of a MAPK1IP1L::TFE3-rearranged renal cell carcinoma","authors":"Burak Tekin,&nbsp;Ruqin Chen,&nbsp;Rumeal D. Whaley,&nbsp;Jordan P. Reynolds,&nbsp;Hussam Al-Kateb,&nbsp;John C. Cheville,&nbsp;Sounak Gupta","doi":"10.1016/j.humpath.2024.105654","DOIUrl":"10.1016/j.humpath.2024.105654","url":null,"abstract":"","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"153 ","pages":"Article 105654"},"PeriodicalIF":2.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142285908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信